| Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-16 14:46:05 |
Czytaj oryginał (ang.) |
| Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails |
DALLAS--(BUSINESS WIRE)--Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer after prolonged use of the company's talc-based products. The filings come as courts across the country prepare to restart proceedings in one of the largest mass torts in U.S. history after a federal bankruptcy judge dismissed J&J's third attempt to shield itself f. |
businesswire.com |
2025-05-15 21:48:00 |
Czytaj oryginał (ang.) |
| If You Invested $25,000 In Johnson & Johnson (JNJ) 20 Years Ago, This Is How Much Cash From Dividends You Would Have Today |
Companies with strong products, good management, solid earnings and growth trends, and a history of annual dividend increases are often popular buy and hold stocks to take advantage of dividend compounding. |
247wallst.com |
2025-05-15 19:34:55 |
Czytaj oryginał (ang.) |
| Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report? |
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-05-15 16:31:08 |
Czytaj oryginał (ang.) |
| Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. |
businesswire.com |
2025-05-14 20:40:00 |
Czytaj oryginał (ang.) |
| The Smartest Dividend Stocks to Buy With $5,000 Right Now |
If you have some spare cash, it's a great idea to put it into some dividend-paying stocks. They're a useful source of passive income that can help supplement your earned income. |
fool.com |
2025-05-14 01:41:00 |
Czytaj oryginał (ang.) |
| Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript |
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us. |
seekingalpha.com |
2025-05-13 18:51:12 |
Czytaj oryginał (ang.) |
| 50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy |
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading. |
seekingalpha.com |
2025-05-12 22:25:11 |
Czytaj oryginał (ang.) |
| Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes |
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China. |
seekingalpha.com |
2025-05-12 19:35:48 |
Czytaj oryginał (ang.) |
| Drugmakers are spared worst-case drug pricing scenario for now |
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan. |
wsj.com |
2025-05-12 17:14:00 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs |
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug. |
zacks.com |
2025-05-12 14:41:06 |
Czytaj oryginał (ang.) |
| J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study |
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis. |
zacks.com |
2025-05-12 13:15:46 |
Czytaj oryginał (ang.) |
| Fortress Dividends: 2 Of The Best All-Weather Income Stocks Built To Last |
Market turmoil often triggers a rush to 'safe' assets, but I believe these moments are best for buying cyclical stocks with strong upside potential. Rather than chasing what's popular, I focus on all-weather dividend stocks, businesses built to deliver steady income through good times and bad. In this article, I present two safe standout players with tremendous turnaround potential, great dividend track records, and attractive valuations. |
seekingalpha.com |
2025-05-11 11:30:00 |
Czytaj oryginał (ang.) |
| Final Trade: SLV, JNJ, HYG, GOOGL |
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. |
youtube.com |
2025-05-09 22:25:54 |
Czytaj oryginał (ang.) |
| 5 Dividend ETFs to Buy and Hold for a Lifetime of Passive Income |
Dividend stock investing offers a reliable path to passive income and long-term wealth creation, making it a cornerstone for many portfolios. By owning shares in companies that pay regular dividends, investors gain consistent cash flow, often from stable, high-quality firms like Coca-Cola (NYSE:KO) or Johnson & Johnson (NYSE:JNJ). Dividends provide a hedge against market volatility, as payouts persist even during downturns, and reinvesting them can compound returns significantly over time. Moreover, dividend-paying stocks historically outperform non-dividend peers, with lower volatility. 24/7 Wall St. Insights: Dividend stock investing has proven a reliable path for investors to gather immense wealth over time. Dividend ETFs bolster those results by investing in hundreds of dividend-paying stocks, offering instant diversification and minimizing single-stock risk. Sit back and let dividends do the heavy lifting for a simple, steady path to serious wealth creation over time. Grab a free copy of “2 Legendary High-Yield Dividend Stocks“ now. Dividend-paying exchange-traded funds (ETFs) enhance these benefits by pooling dozens or hundreds of such stocks, offering instant diversification, reduced single-stock risk, and low expense ratios. In 2025’s uncertain market, marked by tariffs and persistent inflation, dividend ETFs provide resilience and income stability. Pursuing this strategy ensures steady returns and growth, making it ideal for both novice and seasoned investors seeking financial security. Schwab U.S. Dividend Equity ETF (SCHD) Any discussion of dividend ETFs must begin with Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD). It is a top-tier dividend ETF, tracking the Dow Jones U.S. Dividend 100 Index with around 100 high-quality stocks like Lockheed-Martin (NYSE:LMT) and Cisco Systems (NASDAQ:CSCO), each boasting more than 10 years of dividend growth. The ETF’s 3.7% yield and ultra-low 0.06% expense ratio make it cost-effective while limiting sector exposure to no more than 25% ensures diversification. SCHD’s 11.4% annualized return over a decade reflects its balance of income and growth. Because SCHD focuses on financially sound companies, the dividend ETF mitigates risks, offering investors stability. For those seeking high yield and reliability, SCHD stock is a must-own ETF for lifelong passive income. Vanguard High Dividend Yield ETF (VYM) The Vanguard High Dividend Yield ETF (NYSE:VYM) tracks the FTSE High Dividend Yield Index, holding 589 stocks like ExxonMobil (NYSE:XOM) and UnitedHealth Group (NYSE:UNH), with no stock exceeding 4% of the portfolio. VYM’s 2.7% yield and 0.06% expense ratio deliver strong value, while its 13.3% five-year annualized return highlights its consistency. VYM also offers broad diversification across sectors like energy and financials, reducing volatility, making it ideal for conservative investors. With tariff’s top-of-mind for investors these days, the ETF’s U.S.-focused holdings provide resilience against global disruptions. Its proven track record and low costs makes VYM a foundational ETF for steady dividend income and long-term wealth building. Vanguard Dividend Appreciation ETF (VIG) Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) targets companies with over 10 years of dividend increases, such as Microsoft (NASDAQ:MSFT) and Apple (NASDAQ:AAPL), and holds 338 stocks in its portfolio. The ETF’s 1.8% yield is lower, but its focus on dividend growth drives an 11.2% annualized return over the past decade. VIG’s 0.05% expense ratio is also among the lowest, maximizing investor returns. The Vanguard dividend ETF’s tech- and consumer-heavy portfolio suits investors prioritizing capital appreciation alongside income. And for investors looking for exposure to stable, growing firms, VIG cushions against economic uncertainty. It’s another ETF sporting a blend of growth and income, making it a versatile choice for investors seeking a balance of dividends and upside potential. iShares Core Dividend Growth ETF (DGRO) The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) tracks the Morningstar US Dividend Growth Index, holding over 400 stocks like Chevron (NYSE:CVX) and Procter & Gamble (NYSE:PG), and emphasizes its consistent dividend growth. DGRO sports a 2.3% yield and 0.08% expense ratio, offering a balanced income stream and a 16.4% annualized return over five years. The ETF’s diversified sector exposure, including financials and healthcare, minimizes risk. In today’s volatile market, the ETF’s focus on resilient, dividend-growing companies counters the extreme swings the market is experiencing. DGRO’s low cost and steady performance make it an excellent choice for investors seeking dependable income with moderate growth in a challenging economic landscape. ProShares S&P 500 Dividend Aristocrats ETF (NOBL) The last dividend ETF to consider is ProShares S&P 500 Dividend Aristocrats ETF (NYSEARCA:NOBL), which tracks the S&P 500 Dividend Aristocrats Index. It holds over 60 stocks, each with over 25 years of dividend increases, such as Walmart (NYSE:WMT) and C.H. Robinson Worldwide (NASDAQ:CHRW). With a 2.5% yield and 0.35% expense ratio, it reflects NOBL’s premium quality, which has generated 14.5% annualized returns over the last five years. The ETF’s equal-weighted approach also reduces concentration risk, while its focus on elite dividend payers ensures stability. NOBL’s defensive holdings, with a long history of thriving amid uncertainty, offer investors reliable payouts. For those prioritizing quality and consistency, NOBL’s proven resilience makes it a stellar long-term holding for passive income. The post 5 Dividend ETFs to Buy and Hold for a Lifetime of Passive Income appeared first on 24/7 Wall St.. |
https://247wallst.com |
2025-05-09 19:32:05 |
Czytaj oryginał (ang.) |
| J&J's skin disease drug meets main goal in late-stage study |
Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on patients 12 years and older. |
reuters.com |
2025-05-09 12:14:37 |
Czytaj oryginał (ang.) |
| Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis |
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, Pa. , May 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. |
prnewswire.com |
2025-05-09 12:05:00 |
Czytaj oryginał (ang.) |
| 4 High-Yielding Dogs of the Dow Are Crushing the Major Indices |
Investors love dividend stocks, especially high-yield ones, because they offer significant income streams and have substantial total return potential. |
247wallst.com |
2025-05-09 11:13:59 |
Czytaj oryginał (ang.) |
| Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-02-27 12:05:39 |
Czytaj oryginał (ang.) |
| FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled |
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month. |
forbes.com |
2025-02-27 04:53:56 |
Czytaj oryginał (ang.) |
| Johnson & Johnson (JNJ) Could Be a Great Choice |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? |
zacks.com |
2025-02-26 14:45:31 |
Czytaj oryginał (ang.) |
| Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note |
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day. |
zacks.com |
2025-02-25 20:50:35 |
Czytaj oryginał (ang.) |
| INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t. |
businesswire.com |
2025-02-25 14:54:00 |
Czytaj oryginał (ang.) |
| J&J sues Samsung Bioepis over contract breach for Stelara biosimilar |
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug. |
reuters.com |
2025-02-24 19:33:29 |
Czytaj oryginał (ang.) |
| 2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream |
A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure it can maintain its payout during the tough times that inevitably come. |
fool.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Final Trade: TEVA, JNJ, TJX, BABA |
The final trades of the day with the Fast Money traders. |
youtube.com |
2025-02-21 20:27:24 |
Czytaj oryginał (ang.) |
| Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue? |
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-02-21 14:35:28 |
Czytaj oryginał (ang.) |
| TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis |
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction SPRING HOUSE, Pa. , Feb. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn's and Colitis Organization (ECCO). |
prnewswire.com |
2025-02-21 09:00:00 |
Czytaj oryginał (ang.) |
| Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara |
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. |
reuters.com |
2025-02-21 08:44:05 |
Czytaj oryginał (ang.) |
| Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why |
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close. |
zacks.com |
2025-02-19 20:51:46 |
Czytaj oryginał (ang.) |
| AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant |
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of this article is to analyze their updates through Graham's framework for picking defensive stocks. |
seekingalpha.com |
2025-02-19 14:26:10 |
Czytaj oryginał (ang.) |
| Fast Money: CELH, SLV, EEM, JNJ |
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders. |
youtube.com |
2025-02-18 20:20:46 |
Czytaj oryginał (ang.) |
| J&J begins crucial battle over $10 billion baby powder settlement |
Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary's bankruptcy. |
reuters.com |
2025-02-18 08:05:37 |
Czytaj oryginał (ang.) |
| Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon |
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects. |
seekingalpha.com |
2025-02-18 04:25:53 |
Czytaj oryginał (ang.) |
| Johnson & Johnson: Rich History Of Excellence Poised To Endure |
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its ability to drive growth and innovation. The company is well-diversified across thriving healthcare segments, with promising FDA approvals and strategic M&A initiatives enhancing its market position. |
seekingalpha.com |
2025-02-18 04:16:53 |
Czytaj oryginał (ang.) |
| J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold? |
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025. |
zacks.com |
2025-02-17 11:36:10 |
Czytaj oryginał (ang.) |
| J&J resumes US rollout of Varipulse heart device after investigation |
Johnson & Johnson said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended. |
reuters.com |
2025-02-15 02:00:54 |
Czytaj oryginał (ang.) |
| Johnson & Johnson halts late-stage E.coli vaccine trial after poor results |
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds. |
nypost.com |
2025-02-13 13:03:56 |
Czytaj oryginał (ang.) |